107559-05-7

Upstream product

• 618-95-1 methyl 3-nitrobenzoate 
• 618-94-0 3-nitrobenzoic acid hydrazide 
• 65-85-0 benzoic acid 
• 98-88-4 benzoyl chloride 
• 121-92-6 3-nitrobenzoic acid 
• 316149-08-3 N'1-(3-chlorobenzoyl)-3-nitrobenzene-1-carbohydrazide 
• 1673-47-8 3-chlorobenzhydrazide 
• 121-90-4 m-nitrobenzoic acid chloride 
• 74415-21-7 N'-benzoyl-3-nitrobenzohydrazide 
• 1874-38-0 2-(3-nitrophenyl)-5-phenyl-1,3,4-oxadiazole 

Relevant academic research and scientific papers

Pyrimidine type antitumor compounds having 1,3,4-oxadiazole structure and preparation method and application thereof

The invention belongs to the technical field of medicines, relates to compounds having antitumor activity and having specific chemical structures, and particularly relates to pyrimidine type antitumorcompounds having a 1,3,4-oxadiazole structure and a preparation method and application thereof. The general structure formula of the pyrimidine type antitumor compounds is shown as follows in the description. The novel compounds greatly improve antitumor effects, and have more excellent anti-proliferation capability for human lung cancer A549 cells when compared with pyrimidine acylhydrazine compounds. Synthetic steps are simplified in a synthesis process, thus making future industrial production possible.

2,4-Pyrimidinediamine Compounds and Their Uses

The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

Design, synthesis and biological activity evaluation of 2,5-diphenyl-1,3,4-oxadiazole derivatives as novel inhibitors of fructose-1,6-bisphosphatase

Fructose-1,6-bisphosphatase (FBPase), an important gluconeogenic enzyme, catalyzes the hydrolysis of fructose 1,6-bisphosphate to fructose 6-phosphate. The effort to discover new FBPase inhibitors was carried out by high-throughput screening (HTS) of a library of 56,000 lead-like compounds, and a 2,5-diphenyl-1,3,4-oxadiazole (3a, IC50 = 15.45 μM) which bearing no phosphate group was identified as a potential FBPase inhibitor for the first time. Structure-activity-relationship (SAR) research of a series of analogues obtained by modifying the substituent groups and replacing the 1,3,4-oxadiazole with several other heterocycles disclosed the key structure and substituent groups related to the binding with FBPase.